BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nektar Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Nektar Therapeutics's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07690371-70@assetmemo.bio
DTSTAMP:20261121T005931Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:rezpegaldesleukin: Phase 3 readout est. (NCT07690371)
DESCRIPTION:rezpegaldesleukin\, phase 3\, Atopic Dermatitis.\nStudy: A Phas
 e 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age
  With Moderate-to-Severe Atopic Dermatitis\nEstimated primary completion: 
 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rezpegaldes
 leukin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07690371
URL:https://assetmemo.bio/drug/rezpegaldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07711418-70@assetmemo.bio
DTSTAMP:20261121T005931Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:rezpegaldesleukin: Phase 3 readout est. (NCT07711418)
DESCRIPTION:rezpegaldesleukin\, phase 3\, Atopic Dermatitis.\nStudy: A Phas
 e 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age
  With Moderate-to-Severe Atopic Dermatitis\nEstimated primary completion: 
 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rezpegalde
 sleukin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07711418
URL:https://assetmemo.bio/drug/rezpegaldesleukin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
